GSK — Recent News Coverage

All news mentioning GSK in ESEN's AI-graded feed

News stories with GSK as an affected ticker. Each article is graded by ESEN AI for impact level and direction (up/down/flat) on GSK. See /coverage/GSK for the 30-day aggregate.

5 articles Updated: 2026-06-19 12:59 UTC Filter: Ticker: $GSK
SEEKINGALPHA.COM · 2026-06-18 NEUTRAL BULLISH CORR0.35

Spero Therapeutics: Yesterday's Selloff On Utebzi Approval Seems Bewildering (NASDAQ:SPRO)

$SPRO $GSK
◈ ESEN AI
SPRO received FDA approval for Utebzi, a development milestone typically considered positive for biotech firms. The approval unlocks milestone payments and royalty streams via GSK, providing non-dilutive capital and val…
MANILATIMES.NET · 2026-06-17 HIGH BULLISH CORR0.72

Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

$SPRO $GSK
◈ ESEN AI
SPRO and GSK achieved a significant regulatory milestone with FDA approval of Utebzi, the first and only oral carbapenem antibiotic for complicated urinary tract infections (cUTIs). This approval is based on the PIVOT-P…
SEEKINGALPHA · 2026-06-13 NEUTRAL NEUTRAL CORR0.42

Key deals this week: GSK, Incyte, Ingredion, OpenAI, and more

$GSK $INCY $INGR
◈ ESEN AI
This week's deal calendar spans multiple sectors with activity in pharmaceuticals, biotech, specialty chemicals, and artificial intelligence. The presence of mature-stage M&A announcements across diversified industries …
RTTNEWS.COM · 2026-06-12 HIGH BULLISH CORR0.72

Weekly Buzz: GH, LLY Gain FDA Nod; TEVA, GSK, Lead M&A Wave; ZEAL, LLY Post Strong Data

$LLY $TEVA $GSK $ZEAL
◈ ESEN AI
LLY, TEVA, GSK, and ZEAL are driving a significant biotech rally this week, anchored by multiple FDA and regulatory approvals across oncology, dermatology, autoimmune, and rare disease indications. The breadth of approv…
SEEKINGALPHA.COM · 2026-06-11 NEUTRAL NEUTRAL CORR0.35

Nuvalent: 'Hold' On GlaxoSmithKline Acquisition For Selective TKIs (NUVL)

$NUVL $GSK
◈ ESEN AI
Nuvalent (NUVL) faces a strategic valuation inflection point following GlaxoSmithKline's $10.6 billion acquisition announcement. The deal represents a liquidity event for shareholders but introduces meaningful constrain…
EXPLORE OTHER FILTERS